United Therapeutics Corporation
NASDAQUnited Therapeutics enters the post-earnings period with an unusual alignment: options traders turned the most bullish they've been all year on the day the CEO and CFO were selling stock at the open. The insider angle is the story of this week. On May 4, founder and CEO Martine Rothblatt sold roughly 3,680 shares across multiple tranches, collecting around $2.1 million at prices…
Snapshot as of 6 May 2026
United Therapeutics enters the post-earnings period with an unusual alignment: options traders turned the most bullish they've been all year on the day the CEO and CFO were selling stock at the open. The insider angle…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for UTHR — free to start on ORTEX.
Sign up for free →Open UTHR on ORTEX